ArticleFrontiers in medicine2026
Association of 25-hydroxyvitamin D and chemerin with metabolic syndrome components in individuals with type 2 diabetes mellitus.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study investigated the associations of serum 25-hydroxyvitamin D [25(OH)D], the principal circulating marker used to assess vitamin D status, and chemerin with metabolic syndrome (MetS) components in individuals with type 2 diabetes mellitus (T2DM) and in a non-diabetic comparison group. The MetS components assessed were central obesity/waist circumference, blood pressure, fasting plasma glucose, triglycerides, and HDL-C, because these are the diagnostic elements of the International Diabetes Federation (IDF) definition. Methods: This cross-sectional analytical study was conducted at King Abdulaziz University, Rabigh, between August 2021 and December 2022. Participants were classified as having MetS according to IDF criteria, and vitamin D status was classified using serum 25(OH)D concentrations as deficient, insufficient, or sufficient. Serum 25(OH)D, chemerin, and CRP were measured by ELISA. Results: A total of 176 participants were included in the study (88 with diabetes and 88 non-diabetic comparison participants), with equal sex distribution in both groups (44 females and 44 males per group). Compared with the non-diabetic comparison group, participants with T2DM had significantly higher chemerin ( Conclusion: Individuals with T2DM showed lower serum 25(OH)D and increased chemerin concentrations than non-diabetic comparison participants. Chemerin was higher in participants with MetS, whereas neither 25(OH)D nor chemerin was independently associated with MetS in the adjusted logistic model. These findings support an association, rather than a causal or diagnostic relationship, between 25(OH)D, chemerin, and cardiometabolic disturbance in this cohort. Further longitudinal and interventional studies are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.